Podcasts > Archived Podcasts > Industry Focus
This show is no longer producing new episodes. Check out our other shows.
Industry Focus
Healthcare: Why Marijuana Stock HEXO Is on the Hot Seat. And, What's Behind Mylan's Mega-Merger With Pfizer
Jul 31, 2019 (33:09)
Pot stock HEXO is under fire over its use of social media advertising and if that isn't bad enough, its home province, Quebec, has proposed restrictions on marijuana edibles that could disrupt its growth plans. Is it game over for HEXO? Also, here's why biopharma giant Pfizer is merging its off-patent drug portfolio with generic drug heavy weight Mylan.
Check out more of our content here:
- https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" rel="noopener" target="_blank">TMF's podcast portal
- https://www.youtube.com/user/TheMotleyFool" rel="noopener" target="_blank">YouTube
- https://twitter.com/mfindustryfocus?lang=en" rel="noopener" target="_blank">Twitter
- https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group
- https://www.linkedin.com/company/the-motley-fool">LinkedIn
- https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.